Gary.boutte1941@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Entry into a Material Definitive Agreement
On February 25, 2019 (the “Closing Date”), Propanc Biopharma, Inc. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”) pursuant to which the Investor committed to purchase up to $10,000,000 (the “Maximum Amount”) of the Company’s common stock (the “Financing”). In connection with the Financing, on the Closing Date, the Company and the Investor also entered into a Registration Rights Agreement (the “Registration Rights Agreement”, and together with the Purchase Agreement, the “Transaction Documents”). In connection with the execution of the Purchase Agreement, the Company also terminated the Equity Purchase Agreement, dated as of October 5, 2018, between the Company and L2 Capital, LLC. The description of such agreement is set forth in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 10, 2018.
Nice buys today, maybe dilution faucet is coming to an end.
Looks light to .017
Looks like final dump for dilution....couple of million shares diluted!!!
Maybe this is the end and can climb with investors moving into stock.
Congratulations Pennyes...our new MODERATOR!!!!
Keep it real
Hey Mentor...long time no see...lol
Not many on board, few negatives [I can live with that nonsense]
Looks like this will happen starting this Spring with paperwork, trials in late 2019...sounds good!!!
We need a moderator, you did a good job last time.
Yes.. go pass the 1/2 way on video and he talks about the trials.
CEO also mentioned United Kingdom or Australia for startup trials in 2019.
Went back and listened to presentation....you should have caught that, I didn't. lol
Conference news:
Mar - Jun 2019
CRO Selection and contracts
Analytical Labs selection contracts
Trial site[s] selection and contracts
Jul - Oct 2019
Preparation of Logistics
Trial site[s] initiation visits
Nov 2019
First Patient/First visit trials
He mentioned site may be Australia as to where the trials will be held.
Video from BIO conference..First Human Trials.
4 Minute 30 seconds of good news!!!!
Latest Current Report
8-K • February 12, 2019
Current report filing
On PPCB website, click INVESTORS, click SEC filings. Latest 8K dated Feb 12, 2019
click PDF and pull up the 8-K.....30 pages
Page 25 has calendar of 2019/2020 showing preparation and estimated start time for trials.
When PPCB had the Bio conference in 2018, they came out with update within a week.
If they mentioned PROJECTED DEVELOPMENT TIMELINES and Trials to start Nov 2019....we may see our 0.25 again!!!
Keep the faith....good things come to those who wait!
Agree, CEO will give us a re-cap as to how the conference went down. Presentation was only 15 to 30 minutes long...let's see if any company raises an eyebrow.
FYI, I don't offer advice on holdings...retired and play with pennies. Have a measly 435,000 shares in PPCH and waiting, and waiting, and waiting!
I copy/paste information only...sometimes make predictions, but that's pie in the sky. Crystal ball cracked, so I put it away for now...lol
Here is example of loan...10-Q dated 11/13/2018
PROPANC BIOPHARMA, INC. AND SUBSIDIARYNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSSeptember 30, 2018(unaudited)The maturity date of the June 2018 Eagle Note is June 14, 2019. The June 2018 Eagle Note bears interest at a rate of 8% per annum, whichinterest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversionby the Company from Eagle Equities at any time after the six-month anniversary of the June 2018 Eagle Note.Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the June 2018 Eagle Note, at anytime, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock asreported on the OTC quotation system for the ten prior trading days, including the day upon which the Company receives a notice ofconversion from Eagle Equities. However, in the event that the Company’s common stock is restricted by the Depository Trust Company(“DTC”) for any reason, the Conversion Price shall be lowered to 50% of the lowest closing bid price for the duration of such restriction. Ifthe Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion ofthe Note for at least 60 days after the issuance of the Note, the conversion discount shall be increased by 10%. Notwithstanding theforegoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’scommon stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s commonstock. The June 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $70,000 putpremium. The Company has recorded $2,485 of accrued interest and the total principal outstanding under the June 2018 Eagle Note was$105,000 as of September 30, 2018.The June 2018 Eagle Note may be prepaid by the Company with certain penalties until December 11, 2018.Upon an event of default, principal and accrued interest will become immediately payable under the note. Interest on the outstandingprincipal shall accrue at a default interest rate of 24% per annum or at the highest rate permitted by law. Further, certain events of defaultmay trigger penalty and liquidated damage provisions.July 13, 2018 Securities Purchase AgreementEffective July 13, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equitiespurchased a convertible promissory note (the “July 2018 Note”) from the Company in the aggregate principal amount of $75,000, suchprincipal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after thesix month anniversary of the July 2018 Eagle Note. The transaction closed on July 16, 2018 and on July 19, 2018 the Company receivedproceeds of $71,250 as $3,750 was paid directly to legal fees.The maturity date of the July 2018 Eagle Note is July 13, 2019. The July 2018 Eagle Note bears interest at a rate of 8% per annum, whichinterest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversionby the Company from Eagle Equities at any time after the six-month anniversary of the Note.Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the July 2018 Eagle Note, at anytime, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stockfor the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certainevents. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’scommon stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s commonstock. The July 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $50,000 putpremium. The Company has recorded $1,299 of accrued interest and the total principal outstanding under the July 2018 Eagle Note was$75,000 as of September 30, 2018. The July 2018 Eagle Note may be prepaid by the Company with certain penalties until January 9, 2019.Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon anevent of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law.Further, certain events of default may trigger penalty and liquidated damage provisions.August 29, 2018 Securities Purchase
When they borrow money at .01 the payback is massive with interest.
Hope you are correct. I just see they contract for payback on loan at a fixed amount and give a time frame, pass that you pay interest.
And you are right, I've see dilution in .000 and it's in massive amounts.
Just be patient...good things will happen!
One word....DILUTION
When someone loans money to a company....paybacks are hell on the investor. They will get their share before you can blink!
Would be nice if they would advise us when it's over.
Watching the board today, saw dilution up to 800,000 shares...don't think any investor would give up their holdings at this point in the game, maybe they thought it would be completed before the conference...eventually not!
Hi Pennyes...found information on 2019 Bio-CEO conference website.
All information listed on presenters and what they will say at conference.
PROJECTED DEVELOPMENT TIMELINES:
Trials start Nov 2019 after study preparations.
Yea boy!!!! When he makes that statement in the next 1/2 hour, something will fly,,,and it will be movement on stock.
#28,000,000 on hand to start trials!!!!!
The company has raised approx. $18 million and recently entered into a $10 million financing facility with an accredited institutional investor to fund future clinical development activities for our lead product, PRP.
Propanc Biopharma Inc.
James Nathanielsz, Propanc Biopharma Inc.
Propanc Biopharma is a biopharmaceutical company developing new cancer treatments for solid tumors. The company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive precursors of enzymes.
Date:Tuesday, February 12
Time:9:45 AM - 10:00 AM
Room:Hudson/Empire
Location:7th Floor
Session Type:Company Presentation
Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
Company HQ City:Camberwell
Main Therapeutic Focus:Oncology
Company Presentation - Presentation Type:Publicly Traded Company
Year Founded:2007
Submission ID:23328
Ticker:PPCB
CEO/Top Company Official:James Nathanielsz
Market Cap:$5.86 million
Lead Product in Development:PRP (trypsinogen/chymotrypsinogen I.V injection)
Company HQ Country:Australia
Development Phase of Primary Product:Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):1
Company Website:www.propanc.com
Exchange:OTCQB
Additional Information/Comments:Our lead product, PRP, is a solution for intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP prevents tumor recurrence and metastasis from solid tumors. PRP's unique patented approach is designed to target and eradicate cancer stem cells that are not killed by standard treatments. We recently completed preclinical development and are currently undertaking IMP manufacture to commence first-in-human studies in 2019. PRP received Orphan Drug Designation Status from the FDA for the treatment of pancreatic cancer. The company has joint research partnerships with Granada and Jaen Universities, as well as University Hospital in Granada, Spain, known as the Public Health Foundation Network, or FIBAO. The company has raised approx. $18 million and recently entered into a $10 million financing facility with an accredited institutional investor to fund future clinical development activities for our lead product, PRP.
Goal for Presentation:To inform life sciences investors regarding the exciting potential of our breakthrough technology.
Speakers
James Nathanielsz
https://www.propanc.com/
Site will get you up to date.
Chief Executive Officer, James Nathanielsz, will be presenting at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 9:45 am EST. The conference will be held at the New York Marriott Marquis.
“The BIO CEO & Investor Conference is one of the largest investor conferences, focused on established and emerging publicly traded and select private biotech companies, and I am honored to be selected to present at this year’s conference. As we prepare to transition our lead technology into human trials, this is a great opportunity for us to meet with investors and potential partners to provide a company update for 2019, focusing on the advancement of our lead product, PRP,” said James Nathanielsz, CEO and Executive Chairman of Propanc. “PRP is a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a first-in-human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells.”
We may get the anticipation spike today....never know!!!
The conference should indicate when the trials will began, hoping for good news....locked and loaded to meet the challenge.
Agree, better to be a .03 company.....a .015 sounds bad.
Would be nice to see a jump before conference, good news will make it fly.
Any ideas as to when dilution will end....nice buys this morning, wants to run, but sellers are controlling the stock.
Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference
2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 9:45 am EST. New York City
American bulls has BUY alert today:
Signal Update
Our system’s recommendation today is to BUY. The BULLISH HARAMI CROSS pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0167, and our valid average buying price stands now at 0.0169.
We may break that .02 barrier.
A team of Israeli scientists believes a cure for cancer is within reach, even optimistically predicting that it will be found within a year. But at least one expert in the U.S. has questioned the cure's legitimacy and said it's more likely just another claim on a list of "irresponsible and ultimately cruel false promises" for cancer patients.
https://www.foxnews.com/health/cure-for-cancer-israeli-scientists-claim-to-be-on-brink-of-development
California was mentioned looking for $$$$$ and investments.
Been with PPCB so long....I'm starting to dream about my activity,
Dreamed that they made the PR about the trials and the stock went to $1.00, sold and pounded my chest with my $420,000!!!
Next day the stock opened with a major pharma company taking over PPCB and the stock went to $2.00, needless to say I woke up with a tear in my eye...such a dummy!! lol
He's been to New York and California...lots of states left to hit the sidewalk with tin cup. Maybe he should offer pencils to get better payouts.